Iovance Biotherapeutics (IOVA) Net Margin (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Net Margin of 110.61% for Q1 2026, up 12490.0% year-over-year from N/an in Q1 2025, and down 1226.38% quarter-over-quarter from 9.82% in Q4 2025.
Iovance Biotherapeutics (IOVA) Net Margin (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Net Margin for 4 consecutive years, with 110.61% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 12490.0% year-over-year to 110.61%; the TTM figure through Mar 2026 stood at 95.73% (up 8077.0% YoY), while the FY2025 annual figure was 117.84%, up 10902.0% from the prior year.
- Net Margin eased to 110.61% in Q1 2026 per IOVA's latest filing, from 9.82% in the prior quarter.
- Across five years, Net Margin topped out at 9.82% in Q4 2025 and bottomed at 44759.66% in Q2 2023.
- Historically, Net Margin has averaged 9181.01% across 4 years, with a median of 210.89% in 2025.
- Annual changes were most pronounced in 2024 — Net Margin jumped 4444764 bps — and 2025, when it surged 743 bps.
- Iovance Biotherapeutics' Net Margin stood at 24136.51% in 2023, then jumped by 100 bps to 106.66% in 2024, then jumped by 109 bps to 9.82% in 2025, then slumped by 1226 bps to 110.61% in 2026.
- Business Quant data shows IOVA's Net Margin at 110.61% in Q1 2026, 9.82% in Q4 2025, and 135.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -47.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.62% |
| Mar 31, 2026 | -110.61% |
| Dec 31, 2025 | 9.82% |
| Sep 30, 2025 | -135.28% |
| Jun 30, 2025 | -186.27% |
| Mar 31, 2025 | -235.51% |
| Dec 31, 2024 | -106.66% |
| Sep 30, 2024 | -142.71% |
| Jun 30, 2024 | -312.03% |
| Mar 31, 2024 | -15,800.84% |
| Dec 31, 2023 | -24,136.51% |
| Sep 30, 2023 | -24,255.86% |
| Jun 30, 2023 | -44,759.66% |